Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPoP: Preemptive Therapy vs Prophylaxis for CMV Prevention in Kidney Transplant Recipients
NCT06798909Phase 3Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Jul 2025
- Primary completion
- Nov 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valganciclovir in cytomegalovirus infection (CMV), sponsored by University of California, San Francisco. Started Jul 2025; status: recruiting.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06798909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06798909.